The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,001
Zayed, J. A., Al‐Awamleh, N. A., Hamad, M., Hdaib, M. I. M., & Ayesh, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70944 · Cited by 2
Mwipatayi, B. P., Dodd, J., Carnagarin, R., Mori, T. A., Golledge, J., Burrows, S., Watts, G. F., Iida, O., & Schlaich, M. P. (2026) · Journal of Clinical Hypertension · doi:10.1111/jch.70309 · Cited by 1
Lipoprotein(a): a therapeutic target in waiting? Evidently, evidence-based
Zeng, R., & Li, J.-J. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.06.035 · Cited by 1
Accelerating drug discovery with mass spectrometry-driven bioanalytical innovations and beyond
Mwangi, J. N., Hill, R. C., Runnebohm, A. M., Czerwieniec, G. A., & Berna, M. J. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2687591 · Cited by 1
Nadim, M. K., & Akgun, Y. (2026) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2026.104483 · Cited by 1
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 2
Luo, F., Shao, X., Lin, Y., Pang, M., Zhou, S., Chen, R., She, C., Hu, B., Xu, X., & Nie, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.027 · Cited by 1
de Souza, J. G., Ittermann, T., Werner, N., Schipf, S., Friedrich, N., Nauck, M., Miname, M. H., Fernandes, F., Santos, R. D., Ghadri, J., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03289-8 · Cited by 1
Self-citationChoe, H. J., Park, D., Neeland, I. J., Després, J., & Lim, S. K. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag104 · Cited by 1
Lipoprotein apheresis: still needed in many patients, or soon a historical practice?
Schettler, V. J. J., Akgun, Y., Floege, J., & Zoccali, C. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag240
Lipoprotein(a) carries triglyceride species associated with incident cardiovascular disease
Takov, K., Penkov, S., Pechlaner, R., Elbahtety, E., Yap, L. E., Schmidt, L. E., Berry, S. E., Hall, W. L., Singh, B., Willeit, J., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121866 · Cited by 1
Self-citationLipoprotein(a) and calcific aortic stenosis: from inherited risk marker to therapeutic target
Epelde, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1908850 · Cited by 1
Lipoprotein(a): from the complex metabolism to the optimal lowering drug
Barbagallo, F. D. G., Berteotti, M., Bosco, G., Cosco, L., Pino, A. D., Alfano, F., Piro, S., Scicali, R., Masana, L., & Marcucci, R. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04492-x · Cited by 1
Palabıyık, E. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01033-8 · Cited by 1
Nissen, S. E., Návar, A. M., Krege, J. H., Wei Min, N. I., John, J. S., Nicholls, S. J., Shen, X., Wolski, K., & Michael, L. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.07.015 · Cited by 1
Lipoprotein(a) management simplified: The National Lipid Association lipid simplified series
Koschinsky, M. L., & Ballantyne, C. M. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.013 · Cited by 1
The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests
Superko, H. R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_15 · Cited by 1
Lan, N. S. R., Dwivedi, G., & Bell, D. A. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.03.280 · Cited by 1
¿Qué es el riesgo cardiovascular residual? Etiología, lípidos e inflamación
Badimón, L., Vilahur, G., Padró, T., & Mendieta, G. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00008-0 · Cited by 1
Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference
Sekhar, A., Kuttan, A., & Lange, R. A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001144 · Cited by 1
Hou, G., Alissa, M., Alsuwat, M. A., Alarjany, H. M. A., Alzahrani, K. J., Althobaiti, F. M., Mujalli, H. M., Alotaiby, M. M., Al-Doaiss, A. A., & Anthony, S. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102627 · Cited by 1
Lipoprotein(a): Are we ready for large-scale clinical trials?
Zheng, S., Fang, G., Du, J., & Dong, J. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132236 · Cited by 1
Pavlyha, M., Hunter, M. D., Nowygrod, R., Patel, V. I., Morrissey, N. J., Bajakian, D. R., Li, Y., & Reyes‐Soffer, G. (2024) · JVS Vascular Science · doi:10.1016/j.jvssci.2024.100211 · Cited by 1
The implications of measuring lipoprotein(a) in clinical practice
Barbir, M., Pottle, A., & Bornstein, S. R. (2024) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2024.40 · Cited by 1
Sciahbasi, A., Russo, P., Zuccanti, M., Chiorazzo, L., Castelli, F., & Granatelli, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237420 · Cited by 1
SMASH: An initiative for equitable access to precision medicine for rare or severe lipid disorders
Larouche, M., Abifadel, M., Catapano, A. L., Cuchel, M., Santos, R. D., Raal, F. J., & Gaudet, D. (2024) · European Atherosclerosis Journal · doi:10.56095/eaj.v3i3.78 · Cited by 1
Perspectives on early health economic evaluations of RNA therapies targeted at lipoprotein(a)
Burvill, A., Watts, G. F., & Ademi, Z. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000904 · Cited by 1
Reducing the risk of heart attack: the key role of lipid profiling and atherosclerosis imaging
Biccirè, F. G., Mastroianni, F., Celeski, M., Gatto, L., & Prati, F. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf010 · Cited by 1
A new journal for the cardiovascular community
Lüscher, T. F., & Crea, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf544 · Cited by 1
Biologic therapy for dyslipidemia
Karásek, D. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.054 · Cited by 1
Zavrtanik, M., Likozar, A. R., & Šebeštjen, M. (2021) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3057
Puri, R., Mehta, V., Iyengar, S. S., Srivastava, M. V. P., Yusuf, J., Pradhan, A., Pandian, J. D., Sharma, V. K., Renjen, P. N., Muruganathan, A., et al. (2021) · Current Vascular Pharmacology · doi:10.2174/1570161119666211109122231 · Cited by 1
Welche Risikofaktoren gibt es und was kann man dagegen tun?
Hambrecht, R., & Wienbergen, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63467-7_2 · Cited by 1
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
Kumar, P., Aedma, S. K., Varadarajan, P., & Pai, R. G. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.10.021 · Cited by 1
Elevated Lipoprotein(a) Linked to Recurrent Cardiovascular Events – A Case Report
Roșca, A., Ion, B., & Mihăilă, T. (2022) · Journal of Interdisciplinary Medicine · doi:10.2478/jim-2022-0014 · Cited by 1
Results of Therapy at a Lipid Clinic in Patients with Elevated Lipoprotein(a) levels
Julius, U., Winter, K., Tselmin, S., Schatz, U., Weiss, N., & Fischer, S. (2022) · doi:10.33582/mpcvm.2022.202203002 · Cited by 1
Antisense Oligonucleotide Therapy to Treat Elevated Lipoprotein(a)
Tsimikas, S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_22 · Cited by 1
Self-citationThanh, H. T. (2023) · Tạp chí Tim Mạch Học Việt Nam · doi:10.58354/jvc.106.2023.475
Quest for pharmacotherapy in aortic valve stenosis: the lipid hypothesis
Zheng, K. H., & Dweck, M. R. (2020) · Heart · doi:10.1136/heartjnl-2020-317188 · Cited by 1
Lipoprotein(a) and Incident Atrial Fibrillation
Kim, D. S., & Khandelwal, A. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.026 · Cited by 1
Benson, M. D. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.06.008 · Cited by 1
Baylis, R. A., Wang, F., Gao, H., Bell, C., Luo, L., Nead, K. T., Neilan, T. G., Ross, E., Klarin, D. M., & Leeper, N. J. (2022) · medRxiv · doi:10.1101/2022.11.08.22282072 · Cited by 1
Lipoprotein(a): Solving the Puzzle, Deciphering the Riddle, Unraveling the Enigma
Thanassoulis, G. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.018 · Cited by 1
Nicholls, S. J. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae037 · Cited by 1
AAV-Delivered Anti-PC-OxPL Antibody Fragments: A Novel Therapeutic Approach to Target ALSPreprint
Gomes‐Duarte, A., Wong, J. K., Pasteuning-Vuhman, S., Pos, W., Haselberg, R., Sogorb-González, M., Pascoal, S., van Dijk, R. E., Sharifi, F., Giera, M. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.22.634350 · Cited by 1
Self-citationElevated Lipoprotein(a): A Treatment Challenge and a Practical Solution
Schade, D. S., Adolphe, A., Wann, S., & Eaton, R. P. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.05.035 · Cited by 1
Lowering lipoprotein(a): inhibiting production or enhancing clearance?
Ammar, M., & Mora, S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag132 · Cited by 1
Lipoprotein(a) After HORIZON: Causal Culprit, Risk Marker, or Unfulfilled Therapeutic Promise?
Borovac, J. A., & Belančić, A. (2026) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484261492865 · Cited by 1
Lp(a) (Lipoprotein[a]), an Exemplar for Precision Medicine
Hopewell, J. C., Clarke, R., & Watkins, H. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315549 · Cited by 5
Parhofer, K. G. (2020) · Der Internist · doi:10.1007/s00108-020-00799-9
Cardiology Update 2020 First Quarter
Yadav, S. (2020) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_15_20
Universal cholesterol screening of youth—Are pediatric lipidologists smarter than a fifth grader?
Kohn, B., & Wilson, D. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.09.007
Perspektiven neuer lipidsenkender Substanzen für die Praxis
Klose, G. (2020) · CardioVasc · doi:10.1007/s15027-020-3424-x
Altmann, C., Preuss, T., Schäfer, M., & Panzner, I. (2020) · Gefässchirurgie · doi:10.1007/s00772-020-00728-y
Spezifische Behandlung der Lipoprotein(a)-Hyperlipoproteinämie
Langhammer, R., & Laufs, U. (2020) · CardioVasc · doi:10.1007/s15027-020-3456-2
Kaiser, S. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200303
Sinning, D., & Landmesser, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8496
Emerging New Lipid-Lowering Therapies in the Statin Era
Jang, A. Y., Jo, S., & Koh, K. K. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e5
Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease
Winkler, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822258-4.00010-9
Lipidsenkung jenseits des LDL-Cholesterins
Katzmann, J. L., & Laufs, U. (2021) · Kardiologie up2date · doi:10.1055/a-0897-2742
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
Windler, E. E. T., Zyriax, B., & Augustin, M. (2021) · Gynäkologische Endokrinologie · doi:10.1007/s10304-021-00418-2
Risk Stratification for Adverse Events after Carotid Endarterectomy
Timmerman, N. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/917
Oremek, G. M., Passek, K., Dröge, J., Holzgreve, F., & Ohlendorf, D. (2021) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-021-00452-8
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_9-1
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Individuelle kardiovaskuläre Risiken der Patientin in der Lebensmitte
Windler, E. E. T., Zyriax, B., & Augustin, M. (2022) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-022-00231-5
Kosten-Nutzen-Analyse neuer Lipidsenker
Blaum, C. M., Arnold, N., & Waldeyer, C. (2022) · Herz · doi:10.1007/s00059-022-05116-8
RNA-based Therapeutics in Cardiology: Dawn of a New Era?
Yu, D. B. (2022) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2022.15.002143
Chilazi, M. J., Zheng, W., Park, J., Marvel, F. A., Khoury, S. R., Jones, S., & Martin, S. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.006
Farnier, M. (2021) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(21)45461-9
Primär genetische Dyslipoproteinämien und Atheroskleroserisiko
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_3
Eapen, D. J., Faaborg-Andersen, C. C., DeStefano, R. J., Karagiannis, A. D., Quintana, R. A., Dhindsa, D. S., Chaudhuri, M., Searles, C. D., & Sperling, L. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00026-5
Coronary Artery Calcium-Based Approach to Lipid Management
Kole, A., & Joshi, P. H. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00704-z
Cholesterol: how to measure and how to treat
Pottle, A. (2022) · Practice Nursing · doi:10.12968/pnur.2022.33.10.402
Klose, G., Gouni‐Berthold, I., & März, W. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00178-9
Self-citationLp(a): A New Star of Preventing Cardiovascular Events
漆, 晨. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121592
Research Progress of Lipoprotein a in Cardiovascular Disease
谭, 兴. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.131042
Song, C. K., Keller, T., Regitz‐Zagrosek, V., Steinhagen‐Thiessen, E., Buchmann, N., & Demuth, I. (2023) · Research Square · doi:10.21203/rs.3.rs-2498798/v1
Self-citationLipoprotein(a) in Cardiovascular Disease: Evidence from Large Epidemiological Studies
Thomas, P. E., Vedel‐Krogh, S., & Nordestgaard, B. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_15
Self-citationMillar, J. S., & Rader, D. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_4
Lipoprotein Apheresis for Reduction of Lipoprotein(a)
Julius, U., & Tselmin, S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_23
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Cho, L., & Nissen, S. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00026-1
Bond, R. M., & Ferdinand, K. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00039-x
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 1
The New Fat Kid on the Block: Lipoprotein (a)
Hussein, M. T. E., & Lewis, S. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104731
Lipoproteína (a) y oligonucleótidos antisentido
Romero, J. A. C., Gomez, K. G. C., Ortigoza, M. P. M., & Saavedra-López, H. F. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.3.808
Lipoprotein (a) Concentration is Inversely Related with Vertebral Arterial Flow
Naser, A. (2023) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2023.36744
Hao, X., Jin, A., Xue, J., Cheng, A., Feng, Z., Lin, J., Li, H., Meng, X., Wang, B., Xu, J., et al. (2023) · medRxiv · doi:10.1101/2023.09.27.23296262
The future is now: promising therapies
Ruiz, Á. J., Campo, R., Román-Gonzaléz, A., & Santos, R. D. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000215
Lipidtherapie: Was leisten heutige Behandlungsoptionen?
Brath, H. (2023) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-023-00213-3
Miguel, S. L., & Pardo, D. E. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.3.art2
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
Parsamanesh, N., Poudineh, M., Siami, H., Butler, A. E., Almahmeed, W. A., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.009 · Cited by 1
de Prada, M. G., Segovia, R. C., Martínez, M. D. C., Hidalgo, N. V., López, M. B. S., & Echevarría, A. B. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.12.001
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013
Progress of Clinical Research on Lipoprotein a and Cardiovascular Diseases
郑, 采. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142326
New Hope for Secondary Prevention of Coronary Disease
Patnaik, A. N. (2024) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636231221043
Harris, G., Chuen, J., Farouque, O., Hare, D. L., & Hoi, A. Y.-B. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15087
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
